159 related articles for article (PubMed ID: 31880065)
1. Macular oedema and changes in macular thickness in multiple sclerosis patients treated with fingolimod.
Nørgaard TL; Andersen CU; Hilt C; Andersen CU
Basic Clin Pharmacol Toxicol; 2020 Jun; 126(6):492-497. PubMed ID: 31880065
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing-remitting multiple sclerosis.
Fruschelli M; Capozzoli M; Gelmi MC; Masi G; Annunziata P
Int Ophthalmol; 2019 Apr; 39(4):777-781. PubMed ID: 29500696
[TBL] [Abstract][Full Text] [Related]
3. Famous.
Kim MJ; Bhatti MT; Costello F
Surv Ophthalmol; 2016; 61(4):512-9. PubMed ID: 26742785
[TBL] [Abstract][Full Text] [Related]
4. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis.
Winges KM; Werner JS; Harvey DJ; Cello KE; Durbin MK; Balcer LJ; Calabresi PA; Keltner JL
J Neuroophthalmol; 2013 Dec; 33(4):322-9. PubMed ID: 24051419
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effect of fingolimod (FTY720) on macular perfusion by swept-source optical coherence tomography angiography in patients with multiple sclerosis.
Karaküçük Y; Gümüş H; Eker S
Cutan Ocul Toxicol; 2020 Sep; 39(3):281-286. PubMed ID: 32657164
[TBL] [Abstract][Full Text] [Related]
6. Real-world incidence of fingolimod-associated macular oedema.
Goh LY; Kirthi V; Silber E; Harvey JP; Jackson TL
Mult Scler Relat Disord; 2020 Jul; 42():102125. PubMed ID: 32403070
[TBL] [Abstract][Full Text] [Related]
7. Two-year macular volume assessment in multiple sclerosis patients treated with fingolimod.
d'Ambrosio A; Capuano R; Rossi S; Bisecco A; Lanza M; Gesualdo C; Leocani L; Rodegher M; Filippi M; Marino C; Maimone D; Tedeschi G; Simonelli F; Gallo A
Neurol Sci; 2021 Feb; 42(2):731-733. PubMed ID: 33033898
[TBL] [Abstract][Full Text] [Related]
8. Microcystic macular oedema in multiple sclerosis is associated with disease severity.
Gelfand JM; Nolan R; Schwartz DM; Graves J; Green AJ
Brain; 2012 Jun; 135(Pt 6):1786-93. PubMed ID: 22539259
[TBL] [Abstract][Full Text] [Related]
9. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study.
Saidha S; Sotirchos ES; Ibrahim MA; Crainiceanu CM; Gelfand JM; Sepah YJ; Ratchford JN; Oh J; Seigo MA; Newsome SD; Balcer LJ; Frohman EM; Green AJ; Nguyen QD; Calabresi PA
Lancet Neurol; 2012 Nov; 11(11):963-72. PubMed ID: 23041237
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod treatment in multiple sclerosis leads to increased macular volume.
Nolan R; Gelfand JM; Green AJ
Neurology; 2013 Jan; 80(2):139-44. PubMed ID: 23223539
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod-associated macular edema: A case report of late onset.
Karakosta C; Kourentis C
Eur J Ophthalmol; 2022 Jul; 32(4):NP56-NP60. PubMed ID: 33645300
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod Associated Bilateral Cystoid Macular Edema-Wait and See?
Pul R; Osmanovic A; Schmalstieg H; Pielen A; Pars K; Schwenkenbecher P; Sühs KW; Yildiz Ö; Frank B; Stangel M; Skripuletz T
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983657
[TBL] [Abstract][Full Text] [Related]
13. Progressive Functional and Neuroretinal Affectation in Patients With Multiple Sclerosis Treated With Fingolimod.
Garcia-Martin E; Ruiz de Gopegui E; Satue M; Gil-Arribas L; Jarauta L; Ara JR; Martin J; Fernandez FJ; Vilades E; Rodrigo MJ
J Neuroophthalmol; 2021 Dec; 41(4):e415-e423. PubMed ID: 34788241
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod-associated macular oedema.
Jasani KM; Sharaf N; Rog D; Aslam T
BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28619738
[No Abstract] [Full Text] [Related]
15. Effect of fingolimod therapy on quantitative macular changes among patients with relapsing-remitting multiple sclerosis: a four-year follow-up study from Oman.
Al-Rashdi AA; Sabt BI; Al-Mujaini AS
BMC Ophthalmol; 2022 Dec; 22(1):470. PubMed ID: 36471269
[TBL] [Abstract][Full Text] [Related]
16. Early and recurrent macular oedema in a patient treated with fingolimod.
Cifuentes-Canorea P; Nieves-Moreno M; Sáenz-Francés F; Santos-Bueso E
Neurologia (Engl Ed); 2019 Apr; 34(3):206-207. PubMed ID: 27776961
[No Abstract] [Full Text] [Related]
17. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
Zarbin MA; Jampol LM; Jager RD; Reder AT; Francis G; Collins W; Tang D; Zhang X
Ophthalmology; 2013 Jul; 120(7):1432-9. PubMed ID: 23531349
[TBL] [Abstract][Full Text] [Related]
18. [Cystoid macular oedema after fingolimod treatment in multiple sclerosis].
Asensio-Sánchez VM; Trujillo-Guzmán L; Ramoa-Osorio R
Arch Soc Esp Oftalmol; 2014 Mar; 89(3):104-6. PubMed ID: 24269406
[TBL] [Abstract][Full Text] [Related]
19. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report.
Ueda N; Saida K
BMC Ophthalmol; 2015 Oct; 15():135. PubMed ID: 26481728
[TBL] [Abstract][Full Text] [Related]
20. Uveitic macular oedema: correlation between optical coherence tomography patterns with visual acuity and fluorescein angiography.
Tran TH; de Smet MD; Bodaghi B; Fardeau C; Cassoux N; Lehoang P
Br J Ophthalmol; 2008 Jul; 92(7):922-7. PubMed ID: 18577643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
